Supplier
Baltimore Oncology Hematology Associates LLC
Baltimore Oncology Hematology Associates LLC was paid $1.31M by Medicaid between Mar 2018 and Dec 2024, across 18 billing codes. Its largest line is J2323, Injection, natalizumab, 1 mg — 69% of everything it billed.
33Billing provider infoBALTIMORE ONCOLOGY HEMATOLOGY ASSOCIATES LLC
BALTIMORE, MD 21201
BALTIMORE, MD 21201
33aNPI1598972259assigned 05/16/2007
33bProvider typeNon-Pharmacy Dispensing Site
28Total paid$1.31M
24GClaims15,330
24DCodes billed18
24AFirst – last monthMar 2018 – Dec 2024
Compared with peers
Next to other Non-Pharmacy Dispensing Site providers in Maryland
Rank by total paid#3 of 9
Median peer was paid$554K
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 87 | $464.57 | |
| 2019 | 91 | $993.40 | |
| 2020 | 3,229 | $96K | |
| 2021 | 3,234 | $81K | |
| 2022 | 4,660 | $126K | |
| 2023 | 2,959 | $619K | |
| 2024incomplete | 1,070 | $388K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J2323 | Injection, natalizumab, 1 mg | 69% | 395 | 246 | $899K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 11% | 1,721 | 1,151 | $141K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 9.3% | 3,719 | 2,257 | $121K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 5.7% | 2,392 | 1,646 | $74K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.5% | 2,368 | 1,658 | $33K |
| 96415 | 1.4% | 409 | 235 | $18K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 230 | 89 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 276 | 147 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 575 | 324 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 41 | 25 | $3K |
| 96367 | <1% | 81 | 70 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,519 | 1,158 | $1K |
6 more codes
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 188 | $775.66 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 819 | $687.20 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 14 | $591.48 |
| 36415 | Collection of venous blood by venipuncture | <1% | 317 | $466.17 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 23 | $301.50 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 243 | $217.71 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKALRA, KAVITA (PRESIDENT)